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Effects of atrial natriuretic peptide in clinical acute renal failure.
Fifty-three consenting patients meeting clinical and urine composition
criteria for established intrinsic ARF were assigned to two treatment
groups. Group I patients were treated with human atrial natriuretic
peptide (ANP) with or without diuretics. Groups II patients were
treated with or without diuretics and with no ANP. Age, sex, etiology
of ARF, entry serum creatinines (Sr) (Group I, 5.3 1.8; Group II, 5.1
2.1 mg/dl) and creatinine clearances (Car) (Group I, 9.9 2.1; Group
II, 9.2 2.1 mI/mm) were similar. Thirty patients received ANP [0.20
g/kgImin i.v. x 24 hr (N = 20) or 0.08 g/kg/min i.a. x 8 hr (N = 10)]
and furosemide, 0.5 mg/kg/hr x 24 hr or mannitol, 12.5 g every six
hours x 4, or no diuretic; 23 Group II patients received diuretics as
above or no diuretic in a similar distribution to Group I. C. (verified
with simultaneous inulin clearances x 12, r = 0.93, P < 0.001)
increased significantly by eight hours of ANP treatment to 17.1 3.2
mi/mm and by 24 hours after discontinuing ANP to 21.0 4.4 mI/mm
(both P < 0.05). There was no corresponding increase in Ce,. in Group
II. Dialysis was required in 23% of Group I and in 52% of Group II
patients (different at P < 0.05). Mortality rates of 17% for Group I and
35% for Group II were not significantly different (P = 0.11). It is
concluded that parenteral ANP increases Cr and reduces need for
dialysis in patients with established intrinsic ARF.
Acute renal failure (ARF) is a serious disorder with an
average patient mortality of 50% [1]. Over the past three
decades, a variety of therapeutic maneuvers have been em-
ployed in an attempt to accelerate recovery and reduce the
mortality from ARF. The approaches used have included mod-
ifications of dialysis, nutritional regimens and pharmacologic
agents. Initial studies suggested that early and intensive dialysis
to achieve near biochemical normalcy would limit the duration
and improve ARF patient survival [2—4]. Similarly, hyperali-
mentation formulas containing glucose and essential amino
acids were thought to augment the rate of return of renal
function and decrease mortality [5, 6]. Unfortunately, neither
dialysis nor nutritional manipulations have subsequently been
shown to have a clear impact on the natural history or outcome
from ARF [7—9]. A series of studies involving relatively small
numbers of patients showed encouraging results indicating that
mannitol or ioop diuretics alone or in combination with dopa-
mine reversed oliguric ARF 110—121. However, the lack of large
or controlled trials has left the issue of pharmacologic efficacy
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of these agents unresolved, and no clinical consensus regarding
their use has subsequently emerged. Moreover, the available
data indicate that diuretics and dopamine are of little value
unless they are used early in the course of ARF [11, 121, a
window of time that often goes unrecognized clinically. In
short, it is generally acknowledged that no treatment interven-
tion since the advent of dialysis has had a significant effect on
the duration of or mortality from clinical ARF.
Recently, several animal studies have indicated that atrial
natriuretic peptides (ANP) attenuate the severity and/or accel-
erate recovery in experimental models of ischemic and nephro-
toxic ARF [13—181. The unique feature of these reports was that
ANP was effective if given after, rather than before or during,
the ischemic or nephrotoxic insult. This characteristic of ANP
has made it attractive as a potentially useful agent in the
treatment of clinical acute renal failure, since this disorder can
be predicted or anticipated only in special situations and is
infrequently recognized before it is actually established. In
addition, ANP has been shown to directly increase glomerular
filtration rate (GFR) in pathophysiologic states by altering pre-
and post-glomerular vascular resistances to increase glomerular
capillary hydraulic pressure [16]. ANP also has been shown to
have direct diuretic and natriuretic effects on the distal nephron
[19]. These pharmacologic properties make ANP an ideally
suited substance to counteract two proposed pathophysiologic
mechanisms of GFR reduction in ARF: reduced glomerular
perfusion and tubular obstruction.
Based on the encouraging animal experimental results and
the unique combination of pharmacologic properties, a protocol
was designed to test the therapeutic efficacy and safety of ANP
in the management of clinical ARF. Patients were treated with
a regimen consisting of ANP with or without a diuretic agent or
a similar regimen without ANP. Creatinine clearance, urine
flow rate, the need for dialysis and mortality were compared
between the two treatment groups and form the basis of this
report.
Methods
Patients with established intrinsic acute renal failure at three
University of Colorado Health Sciences Center affiliated hos-
pitals (University, Veterans Affairs and Denver General) were
entered in the study. Entry criteria for established intrinsic
ARF included a deterioration in kidney function in a setting of
ischemic or nephrotoxic insult in which serum creatinine (SCr)
has risen by >0.7 mg/dllday for at least three days to a level
>2.5 mg/dl; urine sodium (UNa) and fractional excretion of Na
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Fig. 1. Identity plot of simultaneously measured endogenous creati-
nine clearances and mu/in clearances in a series of acute renal failure
patients. The correlation coefficient, r 0.93 (P < 0.001), indicated that
endogenous creatinine clearance was a valid method for detecting
changes in glomerular filtration rate.
(FENa) in the absence of diuretics for at least 12 hours >20
mEq/liter and >1%, respectively; urine to serum creatinine
ratio <20, and urine sediment demonstrating formed elements
consistent with acute tubular necrosis. Patients with acute
vascular, glomerular and interstitial inflammatory disorders
were excluded on the basis of clinical examination, urine
sediment and other appropriate laboratory determinations. All
patients had ultrasound examination to exclude urinary tract
obstruction. Urine flow rate was not an entry criterion. Patients
with baseline heart rates <50/mm or systolic arterial pressures
<90 mm Hg, a myocardial infarction within five days or prior
dialysis were excluded.
Following patient identification and informed agreement to
study participation, diuretic agents were withheld and creati-
nine clearances (Car) determined from two sequential four-hour
urine collections and serial serum measurements. To validate
the use of Cr to estimate glomerular filtration rate in ARF
patients, simultaneous inulin clearances (C1a) were performed
on 12 occasions. Results of simultaneous measurements of C1
and C1, are shown in Figure 1. Creatinine clearance was
significantly greater than C1 (P < 0.05),but the mean difference
was only 2.1 0.9 mI/mm. More importantly, the correlation
coefficient between these two GFR estimates was r =0.93 (P <
0.001). Thus, C1 was considered a reliable means of detecting
true changes in effective GFR in ARF patients. Other baseline
measurements during the eight-hour pretreatment period in-
cluded hourly determinations of heart rates, arterial pressures
and urine outputs, continuous electrocardiographic monitoring,
complete blood count, serum electrolytes, serum aspartate
transaminase, serum alkaline phosphatase, serum creatinine
phosphokinase, prothrombin time and partial thromboplastin
time. In addition, daily nitrogen intake—enternal and parenter-
al—was calculated for the entry date and daily thereafter for
patients subsequently requiring dialysis.
Specific treatment regimens
Group I. ANP was administered either intrarenally through
catheters placed in both renal arteries at a dose of 0.08
g/kg/min (0.04 g/kg/min per kidney) for eight hours or intra-
venously at an initial dose of 0.08 pg/kg/min which was in-
creased every 30 minutes thereafter by 0.04 g/kg/min to a final
dose of 0.16 to 0.24 jsglkg/min which was continued for a total
of 24 hours. The first five patients were treated with 3-28 met
human atrial natriuretic factor (L-364670; Merck Sharp &
Dohme, West Point, Pennsylvania, USA); all subsequent pa-
Dopamine, dobutamine and norepinephrine treatment were
restricted in all patients to use only as pressor agents for
hypotension throughout the patient's hospital course. Calcium
channel blockers were restricted except as considered essential
for angina treatment. In no case was a calcium channel blocker
begun after entering a patient in the study. Diuretics were not
used after the 24-hour treatment period described above.
Patients were assigned to a treatment regimen which did
(Group I) or did not (Group II) include ANP. During the three
years in which the study was carried out, both deterministic
sequential and randomization methods were used. The first five
patients meeting entry criteria were assigned to Group I con-
sisting of intra-arterial or intravenous ANP therapy alone. This
sequential method of patient assignment was chosen to assess
initial safety concerns of ANP and the intrarenal and intrave-
nous routes of administration. Thereafter, three successive
patients were pre-assigned to Group II (no ANP) prior to their
actual entry in the study. They received no second drug
treatment. Following this, patients were assigned from a com-
puter generated random number sequence to Group Ito receive
ANP intra-arterially or intravenously plus furosemide or to
Group II to receive furosemide alone. Thereafter, a determin-
istic sequential assignment scheme was again used in which a
series of nine successive patients were pre-assigned to Group I
to receive intravenous ANP plus mannitol. Following this, the
next eight patients were pre-assigned to Group II to receive
mannitol alone. The return to a deterministic sequential assign-
ment method was considered necessary to assess the potential
deleterious pulmonary osmotic effects of mannitol in estab-
lished ARF. Mannitol was first used with ANP because of the
anticipated protective effect of the latter based on interim
analysis indicating that ANP had diuretic effects in these
patients. After the first five ANP-with-mannitol patients were
treated, it was determined that it was sufficiently safe to use
.
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.
• tients were treated with 4-28 human atrial natnuretic peptide
(WY47,663; AuriculinR hANP; Scios Nova, Mountain View,
• California, USA). Pharmaceutical brochures from drug suppli-
• ers indicated that the hemodynamic, renal and adverse effects
of the two atrial natriuretic peptides were indistinguishable in
humans at the same doses. The preferred route of ANP
0 4 8 12 16 20 24 28 32 administration in the first 18 months of the study was intra-
arterial unless there was a vascular disorder or coagulopathy
that made renal artery catheter placement hazardous or the
patient refused arterial catheterization. However, in the final 18
months ANP was only given intravenously. Regardless of route
or duration of ANP administration, simultaneous second drug
treatment was given as follows: furosemide, 0.5 mg/kg/hr intra-
venously for 24 hours, or mannitol, 12.5 g every six hours
intravenously for 24 hours; or no second drug was given.
Diuretic infusion was begun at the same time as ANP.
Group II. No ANP was administered. One of the second
drugs as outlined above was given alone (that is, furosemide or
mannitol) or no diuretic therapy was given.
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Table 1. Entry characteristics of patients
Group I
(N=30)
Group II
(N=23)
Ageyears 58 17 57 16
Sex 22M/8F 14M/9F
Scrmg/dl 5.3 0.3 5.1 0.4
Ccrmlfiflifl 9.9 2.1 9.2 2,1
Group I comprised patients given ANP with or without diuretic;
Group II patients were given diuretic or no diuretic without ANP.
mannitol alone after the ninth ANP-with-mannitol patient. In
every instance, from patient 1 to patient 53, assignment of a
patient to Group I or Group II treatment was determined prior
to his or her initial evaluation and entry.
Because of continuing concerns regarding the hemodynamic
effects of ANP and the decision not to place intra-arterial
catheters for sham (vehicle) infusion, neither the investigators
nor the primary care physicians were blinded as to assignment
to Group I or Group II. While such an unblinded design
introduced the possibility of bias, safety considerations were
deemed to be of overriding importance. Other measures were
introduced to reduce the likelihood of bias regarding dialysis
requirement (see below).
During and after treatment in Groups I and II, the following
measurements were made: hourly heart rates, arterial pressures
and urine flow rates; continuous electrocardiographic monitor-
ing; sequential eight-hour urine collections and four hour serum
collections for creatinine measurement and Cr calculation for
the 24 hours of treatment; and a 24-hour Crdetermination for
the 24-hour period after treatment based on urine and eight-
hourly Se,. measurements. Serum and urine creatinine were
measured by the picric acid modified Jaffe method [20]. Hema-
tologic and liver function tests performed at baseline as de-
scribed above were repeated at the end of the 24-hour treatment
period. Serum atrial natriuretic peptide levels (both L-364670
and WY47,663) were measured by radioimmunoassay [21] at
baseline, 4, 8, and 12 hours in intra-arterial and baseline, 6, 12,
18, 24 and 30 hours in intravenous ANP-treated patients.
Requirement for dialysis therapy and outcome were recorded
for each patient.
Determination of dialysis need, which followed the guidelines
described for the "non-intensive dialysis" group in Gillum et al
[9], was made by the attending renal physician at each hospital
without the knowledge of the investigators. The dialysis criteria
included fluid overload threatening cardiorespiratory function,
hyperkalemia, encephalopathy, intractable acidosis, serum cre-
atinine >9.0 mg/dl or blood urea nitrogen >100 mgldl. All
dialysis patients were treated with four to five hours of hemo-
dialysis.
Data are expressed as means SE. Analysis utilized four
statistical methods. Simple linear regression was used to com-
pare creatinine and inulin clearances in individual patients.
Means of numerical data for the two treatment groups were
compared by unpaired t-test. Continuous measurements within
a treatment group were compared by one-way analysis of
variance. The need for dialysis and mortality for the two
treatment groups were compared using contingency tables and
Fisher's exact test. Unless otherwise stated, significance was
considered to be P < 0.05.
Table 2. Presumed etiology of acute renal failure
Group I(N=30)
Group II
(N=23)
Ischemia 23 10
Nephrotoxin 1 7
Rhabdomyolysis 2 0
Multifactorial 4 6
Results
Patient characteristics
Fifty-three patients meeting the criteria for established intrin-
sic ARF were entered in the study. Thirty patients were
assigned to Group I (ANP treatment) and 23 patients were
assigned to Group II (no ANP treatment). Age, sex distribution,
pretreatment SCr and Cr were similar between the two groups
(Table 1). Overall there were more men than women owing to
the exclusively male patients entered from the VA Hospital.
However, the total number of patients entered from each of the
three hospitals was similar. Nine patients in Group I and seven
patients in Group II were oliguric (<17 mllhr), a distribution
which was not different.
Etiologies of ARF are given in Table 2. There were signifi-
cantly fewer patients with nephrotoxic ARF in Group I (P <
0.01). Also, there was a tendency toward greater ischemic ARF
representation in Group I (P = 0.07).
Treatment regimens
The distribution of treatment drugs within the two group
regimens are shown in Table 3. Of the 30 patients receiving
ANP, 10 were treated with intra-arterial infusion and 20 with
intravenous infusion. Twenty-five of the patients were simulta-
neously given a diuretic (furosemide or mannitol) and five
patients received no second agent. Of the 23 patients not
receiving ANP, 20 received furosemide or mannitol and three
were given no diuretic. There were no differences in distribu-
tion of second drug therapy between the two groups. Six
patients in Group I and five patients in Group II were receiving
dopamine for arterial pressure support during the 24 hours of
specific ARF treatment. For similar reasons, four patients in
each group were being treated with norepinephrine and one
patient in Group II received dobutamine during the treatment
period.
Serum ANP levels
Peripheral serum levels of ANP in patients treated with intra-
arterial and intravenous atrial natriuretic peptide are shown in
Figure 2. Baseline ANP was similar for intra-arterial or intra-
venous treated patients at 51 9 and 58 13 fmollml,
respectively. As is evident from Figure 2 serum levels increased
markedly with intravenous infusion, reached a plateau level
without evidence of drug accumulation and fell abruptly on
discontinuing infusion. In two patients, ANP was measured at
24 hours just before and 30 minutes after stopping intravenous
infusion. Serum levels fell from 8,280 and 4,996 to 896 and 132
fmollml, respectively, providing further evidence of the rapidity
of ANP clearance. Intra-arterial infusion resulted in an approx-
imate tenfold smaller increase in peripheral serum ANP than
was observed with intravenous treatment even though infusion
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Group I(N=30) Group(N=
II
23)
ANP
Intra-artenal 10 —
Intravenous 20 —
Diuretic (2nd drug)
Furosemide 16 12
Mannitol 9 8
None 5 3
rate was only one-third that given intravenously. There was a
similar rapid decline in serum levels after discontinuing intra-
arterial infusion.
Urine flow rates
The effect of treatment on urine flow rate is shown in Figure
3. Baseline urine flow rates were similar between the two
groups. There were similar increases in urine flow rates for the
initial eight hours of treatment. There was a further small
increase in urine flow rate only in Group II patients from 77
20 to 101 21 mI/hr in the next eight hours. There were no
significant declines in urine flow rate over the 24 hour period
after treatment was discontinued in either group. At no time
before, during or after the treatment period were there differ-
ences in urine flow rate between Group I and II patients.
Creatinine clearances
Creatinine clearances are illustrated in Figure 4. Pretreatment
Ccr were not different between the two groups. Unlike urine
flow rate, Ce,. did not increase during or in the 24 hours after
treatment in Group II. In contrast, Ce,. in Group I patients
increased significantly during the first eight hours of therapy
from 9.9 2.1 to 17.1 3.2 mI/mm (P < 0.05). Over the
remaining 16 hours of treatment Cc was not significantly
greater than the pretreatment value. However, CC. was again
significantly increased over the pretreatment value for the 24
hour period after treatment was discontinued to 21.0 4.4
Table 3. Distribution of treatment drugs
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FIg. 2. Plasma ANP levels in ARF patients determined before, during
and after 8-hour bilateral renal artery infusion at 0.08 pg/kgImin( •) and 24-hour intravenous infusion at 0.16 to 0.24 j.g/kg/min
(O----O). Preinfusion plasma levels were 51 9 and 58 13 fmol/ml,
respectively, for intra-arterial and intravenous ANP-treated patients.
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Fig. 3. Changes in mean urine flow rates for Group I (ANP; ) and
Group II (control; ) patients with treatment. Significant increases in
urine flow rates in both groups occurred in the first 8 hours of treatment
(*P < 0.05). There was a further increase in urine flow rate between 8
and 16 hours of treatment only in Group II ('P < 0.05).
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FIg. 4. Changes in creatinine clearances in Group I (ANP; •) and
Group II (control; D) patients with treatment. There was a significant
increase in creatinine clearance in the first 8 hours of treatment only in
Group I compared to baseline and Group II (*P < 0.05). Creatinine
clearance increase was again significantly greater in Group I than the
preinfusion or corresponding Group II value during the 24 hours after
treatment. There were no significant changes in creatinine clearance in
Group II.
mi/mm (P < 0.05). In comparing the treatment-related C.
responses between the two groups, there was an average 7.2
2.0 mi/mm increase over baseline in Group I, but a 0.3 0.9
mi/mm decrease from baseline in Group II in the first eight
hours of treatment (different at P < 0.05). Similarly, in the
24-hour period post-treatment, there was a mean increase in
Cr over baseline of 11.0 2.9 mi/mm in Group I, which was
greater than the mean increase of 3.9 2.1 mi/mm in Group II
(P < 0.05). At no other intervals during treatment were Ce,,
responses between the two groups significantly different.
Mean serum creatinine profiles for the two groups could be
determined for 48 hours from the initiation of treatment until 24
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Table 4. Patients requiring dialysis
Group I(N=30) Group II(N=23)
Dialyzed 7 (23%) 12 (52%)
Not dialyzed 23 (77%)
P <
11(48%)
0.05
hours after treatment. Thereafter, Srtracking was obscured by
dialysis in a number of patients. The changes in Se,. for this time
period were +0.29 0.23 and +0.85 0.34 mgldl, respectively,
for Group I and Group II. The difference did not achieve
statistical significance.
Need for dialysis
Requirement for dialysis is given in Table 4. Twenty-three
percent of the patients in Group I needed dialysis which was
significantly less than the 52% requiring dialysis in Group II (P
< 0.05). The mean time of dialysis after beginning treatment
was 3.5 days range (2.5 to 5 days) in Group land 4.0 days (range
2.5 to 6.5 days) in Group II. Mean Sr values at the time of first
dialysis were 8.4 1.2 mg/dl in Group I and 9.5 1.8 mg/dl in
Group II. The number of dialyses per patient was not different
for the dialyzed patients in Groups I and 11(3.2 1.7 and 4.7
1.1, respectively). Patient records gave the following indica-
tions for dialysis: Group I, uremic CNS or bleeding concerns in
three, volume overload and respiratory decompensation in
three and serum K of 6.4 mEq/liter in one patient; Group II,
uremic CNS or bleeding concerns in three, volume overload
and respiratory decompensation in six, serum K of 6.3 and 7.0
mEq/liter, respectively, in two, and severe acidosis (pH 7.15,
HC03 6 mEq/liter) in one patient. None of these parameters of
dialysis was different between the two groups. When only
surviving patients were considered, the need for dialysis was
also less for Group I. Five of 25 (20%) of patients in Group I and
7 of 15 (47%) of patients in Group II needed dialysis therapy
(different at P < 0.05). Daily nitrogen intake did not differ in
Group I and II patients receiving dialysis.
Patient outcome
Mortality for Group I and II patients is shown in Table 5.
While there was a trend toward improved survival in Group I (P
= 0.11), the difference did not achieve significance as defined
for this study. Causes of death including heart failure, sepsis,
hemorrhage and arrhythmias were similarly distributed be-
tween the two groups.
Adverse drug reactions
In nine of the 30 ANP-treated patients there were reductions
in systolic arterial pressure of >5 but <15 mm Hg that were
associated either with beginning or increasing the rate of drug
infusion. In no case was drug infusion altered as a result of the
arterial pressure change nor were pressor agents begun or
increased. In one additional patient, who was withdrawn from
the study and data not analyzed, systolic arterial pressure fell to
<90 mm Hg when intravenous ANP infusion was increased to
0.28 p.glkglmin. Reducing infusion rate was inadequate to
restore arterial pressure. ANP infusion was discontinued after a
total of only four hours. There were no other adverse reactions
Table 5. Patient outcome
Group I(N=30) Group II(N=23)
Lived 25 (83%) 15 (65%)
Died 5 (17%) 8 (35%)
that could be attributed to ANP including tachycardic or
bradycardic arrhythmias. Bleeding from intra-arterial catheter
placement was neither sustained nor required transfusion in any
patient. There were no identifiable adverse reactions to furose-
mide or mannitol.
Strat/Ication assessment of ANP treatment
When responses were compared between the eight hour
intra-arterial and 24-hour intravenous ANP treatments, there
were no significant differences in sequential C. determinations
either during or following infusion. There were similar increases
in the first eight hours of treatment and again during the 24 hour
period after discontinuing intravenous ANP which was an
interval between 16 and 40 hours after stopping intra-arterial
ANP. Percentages of patients requiring dialysis and surviving
also were similar in the intra-arterial and intravenous ANP-
treated group. All but one of the patients experiencing small
reductions in arterial pressure and the withdrawn patient with
significant hypotension were given intravenous ANP.
There were no detectable differences in Cr responses or
dialysis requirements associated with the simultaneous use of
either furosemide or mannitol. The probability of response to
ANP treatment was not significantly correlated with pretreat-
ment urine flow rate.
Discussion
There have been several reports regarding the efficacy of
pharmacologic agents to modify the course and outcome of
clinical ARF. Results have been described with the use of
vasoactive agents including dopamine [10—12], alpha-adrenergic
antagonists [22, 23], prostaglandins [24], dihydralazine [25] and
calcium channel blockers [26, 27], and with patient diuretics
such as mannitol [10, 28—30], furosemide [31—33] and ethacrynic
acid [34]. Some of these studies, particularly those using
dopamine in combination with a loop diuretic, suggested that
drug intervention might attenuate ARF severity or shorten
recovery time [11, 12]. Other studies indicated that pharmaco-
logic intervention had no effect on outcome even though urine
flow rate might have been transiently and variably increased
[32, 33]. Regardless of the positive or negative effects reported,
all of these studies were hampered by either very small numbers
of patients and/or the absence of appropriate control groups.
The present investigation regarding the effects of ANP repre-
sents the largest controlled assessment of the effects of a
pharmacologic agent in established ARF of diverse etiologies.
Investigating the efficacy of drug treatment in ARF presented
several difficulties which, in part, may have accounted for the
paucity of controlled studies in the past. These difficulties
included defining the disease entity to be treated, choosing
appropriate endpoints of therapy, providing treatment alterna-
tives sufficiently acceptable to attending physicians and patients
that randomization or sequentially determined assignment was
possible and, finally, the need to simultaneously assess efficacy
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and safety of the study drug. The entry criteria, which in
essence defined established acute renal failure for the purpose
of this study, included the urinary composition elements gen-
erally considered to represent functional "acute tubular necro-
sis" in a setting of antecedent hemodynamic and nephrotoxic
insults [35]. Patientswith urinary electrolyte composition and a
clinical appearance suggesting prerenal azotemia [35]and those
with obstructive, vascular, glomerular or interstitial inflamma-
tory disorders were systematically excluded. Urine flow rate
was not an entry criterion. Approximately two-thirds of the
patients in both treatment groups were non-oliguric which is not
inconsistent with present-day trends for intrinsic ARF presen-
tation [36, 37]. Severity of ARF was an important entry
criterion, since the probability risk had to be substantial for the
dialysis need to be a meaningful endpoint of therapy. Thus, the
rate of rise of SCr chosen was >0.7 mg/dl/day and the minimal
Se,. at the time of entry was >2.5 mg/dl. Significantly fewer
patients with nephrotoxic ARF and a trend toward more
patients with ischemic ARF were entered in Group I. This
distribution was fortuitous, since no attempt was made to match
patients in the two groups by etiology. However, it is unlikely
that the lack of distribution symmetry biased the end point
assessments in favor Group I, since it is generally recognized
that patients with ischemic ARF have less favorable outcomes
than those with nephrotoxic ARF [38].
Switching patient treatment group assignment methods in the
course of the trial was a weakness of the study. Safety concerns
initially about ANP and in the final phase of the study regarding
repeated doses of mannitol in established ARF patients with
tenuous pulmonary status were considered justifiable reasons to
use the sequential rather than random assignment method as
pointed out in the Methods. While no patient was assigned to a
treatment group after evaluation and entry, the design flaw has
to be considered in drawing conclusions from the study.
Therapeutic endpoints were selected by a rationale that
permitted both sensitive assessment of renal function and
practical evaluation of key factors in patient course and out-
come. Creatinine clearance, while not an optimal method to
estimate GFR in the non-steady state conditions of ARF, was
verified by simultaneous measurement of inulin clearance in
several patients. Therefore, it was considered to be the most
practical sensitivity and specificity means of determining the
effect of ANP on kidney performance. Patient mortality was
included as an end point because of its obvious ultimate
importance. However, patient mortality assessment lacked
specificity, since it could be influenced by factors other than
ARF or drug treatment. While serial changes in Se,, over several
days after treatment might have been an appropriate endpoint
of therapy, death from unrelated causes and dialysis interven-
tion obviated the meaningful use of these data except over a
short term. Therefore, while not necessarily ideal, the require-
ment for dialysis was chosen as the primary endpoint of
treatment, since it addressed the seriousness of specific conse-
quences of ARF following the period of pharmacologic treat-
ment. The effects of ANP on creatinine clearance and patient
mortality were selected as secondary endpoints. Unfortunately,
dialysis requirement determination carried the potential for
selection bias. This possibility was eliminated, as far as possi-
ble, by the absence of the investigators from patient care
decisions.
Since the investigators exercised no direct control over renal
or non-renal patient management, a major difficulty in achieving
acceptability of the protocol and the patient assignment format
in the majority of patients was the availability to primary care
physicians of alternate treatment regimens not containing ANP.
This necessitated the simultaneous use of furosemide or man-
nitol in most ANP-treated patients. Even though it was pointed
out that there was no convincing evidence that diuretic therapy
was of proven benefit in ARF patients, most primary physicians
indicated they were reluctant to enter patients if they were
randomized to a group that would not at least receive diuretic
therapy. It is of interest that as the study progressed, several
potential patients were not entered because primary physicians
wanted their patients to receive ANP rather than undergo
randomization or sequential assignment. Another difficulty re-
garding acceptability of the treatment regimens was the use of
intra-arterial ANP. While it was pointed out that the greater
systemic ANP exposure with intravenous infusion could poten-
tially increase the risk of hemodynamic side effects, primary
physicians and patients often were adverse to renal artery
catheter placement even in the absence of ilio-femoral athero-
sclerosis or coagulation disorders. Thus, the option of intrave-
nous ANP was chosen in these patients primarily because of
perceived lower risks regarding local arterial injury.
Previous clinical trials with ANP in patients with edematous
states [39, 40] and in normal individuals [41] reported significant
hemodynamic adverse effects in a dose range similar to that
used in the current study. The major adverse event was
hypotension. Since the study population, by and large, was
composed of seriously ill patients in intensive care settings,
there was substantial concern about hypotensive risk, particu-
larly when ANP was given intravenously at increasing doses to
determine the optimal therapeutic range. Thus, on two occa-
sions successive patients were given ANP at increasing doses
while being closely monitored to assure that doses as high as
0.24 gfkg/min could be tolerated. Unfortunately, this safety
assessment temporarily interrupted the randomization format in
the ANP with furosemide and furosemide alone phase.
Despite the above-cited difficulties in carrying out the proto-
col, acceptable balance of variables between the two treatment
groups emerged that permitted an assessment of the therapeutic
efficacy of ANP. Similar numbers of patients with comparable
ARF severity were treated. The distribution of secondary drug
treatment was comparable as was pressor agent exposure.
Atrial natriuretic peptide infusion, regardless of the route of
administration, resulted in a reduced requirement for dialysis
compared to the group not receiving ANP. The objective
parameters indicating dialysis need were similar for the two
groups, reducing the likelihood that there was bias in determin-
ing dialysis requirement. Creatinine clearances increased sig-
nificantly in the initial eight hours of ANP therapy and during
the 24 hours after the treatment period was concluded. A
similar increase in Crwas not found in Group II patients. The
post-treatment level of Cr in the ANP-treated patients of 21.0
4.4 ml/min, twice the pretreatment level, was consistent with
the substantially lower need for subsequent dialysis. Serial
determinations of S. did not support a substantial effect of
ANP on GFR. On the other hand, the available interval for 5Cr
tracking was short due to interruption by need for dialysis in
some patients.
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The mean baseline serum ANP level for the ARF patients in
this study (52 11 fmol/ml) was higher than that reported for
normal individuals on a high sodium diet of 22 3 fmollml when
a comparable radioimmunoassay was used [21]. Serum levels
increased markedly during ANP infusion to more than 14 times
the baseline level with intra-arterial infusion and more than 120
times the pre-infusion value with intravenous treatment. It is of
interest that despite an ANP infusion rate that was approxi-
mately one-third, peripheral serum ANP levels in intra-arterial
treated patients were only one-tenth that found in intravenously
infused patients. Since serum levels tended to stabilize during
infusion by either route, the markedly lower value with intra-
arterial treatment suggests a major first-pass removal of ANP
by the ARF kidneys. While the kidneys, in addition to the liver
and lungs, are the major physiologic sites of ANP clearance
[421, it was surprising that renal removal, presumably by
vascular C-receptor uptake and neutral endopeptidase metabo-
lism, continued to be a highly efficient process despite the major
decline in renal function. Despite the very high serum levels of
ANP found with intravenous infusion, significant hypotension
was a rare event and there were no episodes of arrhythmias that
could be linked to drug infusion. Only one patient receiving the
highest test dose of ANP (0.28 g/kg/min) required drug dis-
continuation due to blood pressure reduction. Unfortunately,
blood for ANP level was not obtained prior to stopping treat-
ment in this patient.
Comparisons among stratified patient subsets in this study
detected no statistical differences. The effects of intra-arterial
versus intravenous ANP, simultaneous diuretic agents versus
no second drug and oliguric versus nonoliguric pretreatment
status were similar for all study endpoints. However, it cannot
be concluded that one route of ANP treatment or patient group
does not have a greater likelihood of a positive response based
on this study, since the numbers of patients in the stratified
subgroups was too small to avoid the prossibility of a type II
statistical error.
The authors are aware of only one other study examining the
effects of ANP in similar ARF patients. Gotz et al [43] gave 2.5
gImin 1-28 human ANP intravenously for three hours into 13
patients with dopamine and furosemide resistant ARF. There
was an increase in urine flow rate of 50% in non-oliguric
patients, but no effect on glomerular filtration rate. The dose of
ANP on average was one-fifth that infused intravenously in the
present study and the duration of infusion substantially less. No
control group was examined and dialysis requirement and
mortality were not reported. Ratcliffe et al [44] in a related
study found that infusing atriopeptin III intravenously at 0.1
gIkgImin for 12 hours immediately after release of vascular
clamps did not improve Ce,. over the first seven days after renal
transplantation nor dialysis requirement compared to a placebo-
treated group. While it could be inferred that ANP had no effect
on allograft ischemia, comparison with the present study is
difficult because of the substantial differences in patient popu-
lations studied and the uncertainty of pretreatment functional
status of the transplanted kidneys. In addition, the dose and
duration of ANP infusion were less than the present study.
Unfortunately, the measurements made in the present study
provided no insight as to the pharmacologic actions of ANP in
the ARF patients. Based on the effects observed in animal
models [13—18], it can be conjectured that there was increased
hydraulic pressure and blood flow in at least a portion of the
glomeruli. The sustained positive effect on creatinine clearance
after discontinuing treatment would suggest that the glomerular
hydraulic and direct tubular effects of ANP may have re-
established patency of some nephrons by removing obstructing
casts. Atrial natriuretic peptide has been shown to suppress
endothelin release [45]. The latter has been shown to be
elevated in ARF and may contribute to sustained renal vaso-
constriction. If negative effects of ANP occurred in this study,
such as priming of polymorphonuclear leukocytes [461, they
went undetected and did not appear to adversely affect renal
function.
In summary, the results of this modestly sized, but controlled
study in ARF patients demonstrated that short-term parenteral
infusion of ANP could be carried out safely and suggested that
ANP had positive effects on selected endpoints of therapy.
Creatinine clearance was improved, not only during ANP
infusion, but in the post-treatment period as well. The need for
dialysis was significantly reduced compared to patients not
given ANP. Differences in patient mortality with ANP treat-
ment did not reach statistical significance. Interpretation of the
results of this study should be tempered, however, until they
can be reproduced in larger intrinsic ARF study populations.
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